According to Protalix BioTherapeutics 's latest financial reports the company's current revenue (TTM) is $65.49 M. In 2022 the company made a revenue of $47.63 M an increase over the years 2021 revenue that were of $38.35 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $65.49 M | 37.48% |
2022 | $47.63 M | 24.22% |
2021 | $38.35 M | -39.03% |
2020 | $62.89 M | 15% |
2019 | $54.69 M | 7.44% |
2018 | $50.9 M | 164.55% |
2017 | $19.24 M | 109.17% |
2016 | $9.19 M | -234.67% |
2015 | -$6.84 M | -145.06% |
2014 | $15.16 M | 31.68% |
2013 | $11.51 M | -66.56% |
2012 | $34.42 M | 243.45% |
2011 | $10.02 M | 57.89% |
2010 | $6.34 M | 1536.08% |
2009 | $0.38 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Pfizer PFE | $58.49 B | 89,216.58% | ๐บ๐ธ USA |
Neurocrine Biosciences
NBIX | $1.88 B | 2,781.33% | ๐บ๐ธ USA |
Amicus Therapeutics
FOLD | $0.39 B | 509.76% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | $15.84 B | 24,094.58% | ๐ฎ๐ฑ Israel |